Schwarz: The Omeprazole Opportunity

Germany's Schwarz has invested heavily in its transition from a marketing organization into a development-based firm. Higher-than expected windfall revenues from generic omeprazole increase its chances of a successful transformation.

Germany's Schwarz Pharma AG has accepted lower-than-average profits over the last few years as it transforms itself from a branded generics player and local co-marketer into a development-based firm. Realizing in the mid-90s that Big Pharma didn't need co-marketing partners any more, and that prices at home were spiraling downwards, Schwarz accepted just 3-4% annual growth for the sake of heavy investments into a development pipeline of its own.

Not that Schwarz is delving too deeply into development—simply to the depths of a risk-comfort zone that the family-controlled firm...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo